In vivo role of LMO4 and isolation of an LMO4-containing proteosome in breast cancer

LMO4 在乳腺癌中的体内作用以及含 LMO4 的蛋白酶体的分离

• 批准号: nhmrc : 257531
• 负责人: Prof Geoffrey Lindeman
• 金额: $ 30.36万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2003
• 资助国家: 澳大利亚
• 起止时间: 2003-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/vivo-role-lmo4-breast-cancer/80879
• 关键词: vivo; role; LMO4; isolation; containing

Breast cancer is the most common cancer to affect women, with one in 10 developing the disease. Although treatment of breast cancer has substantially improved over the last few years, 25% of women diagnosed with this cancer will die from the disease. A major objective of cancer research is the identification of genes involved in tumour development and definition of their precise role in both normal and cancer cells. The design of effective therapeutic inhibitors of cancer requires an understanding of the basic molecular and cellular biology behind the genetic changes thought to contribute to cancer. The focus of our research is to understand normal cellular mechanisms that drive growth and differentiation of breast tissue, and those changes that lead to breast cancer. Nuclear regulatory proteins have been implicated in many different types of cancers and leukaemias. We aim to identify the key regulators in breast tissue, characterising both their structural properties and biological roles, with the ultimate view of understanding how they divert a normal cell to a cancerous cell. This proposal centres on the characterisation of a specific regulatory molecule which we recently demonstrated to be overexpressed in 56% of human primary breast cancers and in 38% of pre-invasive ductal carcinoma in situ. These studies will include defining its normal biologic function and identification of the proteins that this regulator associates with in breast cancer cells.

乳腺癌是影响女性的最常见的癌症，十分之一的女性会患上这种疾病。虽然乳腺癌的治疗在过去几年中有了很大的改善，但25%的被诊断患有这种癌症的妇女将死于这种疾病。癌症研究的一个主要目标是确定参与肿瘤发展的基因，并确定它们在正常细胞和癌细胞中的确切作用。设计有效的癌症治疗抑制剂需要了解导致癌症的基因变化背后的基本分子和细胞生物学。我们的研究重点是了解驱动乳腺组织生长和分化的正常细胞机制，以及导致乳腺癌的那些变化。核调节蛋白与许多不同类型的癌症和白血病有关。我们的目标是确定乳腺组织中的关键调节因子，描述它们的结构特性和生物学作用，并最终了解它们如何将正常细胞转移到癌细胞。我们最近证明，在56%的人类原发性乳腺癌和38%的浸润前导管原位癌中，一种特定调控分子过表达。这些研究将包括确定其正常的生物学功能，并确定与乳腺癌细胞中该调节因子相关的蛋白质。